Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.

Date publication

janvier 2018

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DI MARTINO Vincent

Tous les auteurs :
Maunoury F, Clément A, Nwankwo C, Levy-Bachelot L, Abergel A, Di Martino V, Thervet E, Durand-Zaleski I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29543897

Résumé

To assess the cost-effectiveness of the elbasvir/grazoprevir (EBR/GZR) regimen in patients with genotype 1 chronic hepatitis C virus (HCV) infection with severe and end-stage renal disease compared to no treatment.

Mots clés

Antiviral Agents, economics, Benzofurans, economics, Cost-Benefit Analysis, methods, Drug Therapy, Combination, economics, Female, France, Genotype, Hepacivirus, genetics, Hepatitis C, Chronic, complications, Humans, Imidazoles, economics, Kidney Failure, Chronic, complications, Liver Cirrhosis, complications, Male, Middle Aged, Models, Economic, Quality-Adjusted Life Years, Quinoxalines, economics, RNA, Viral, genetics, Randomized Controlled Trials as Topic, Renal Dialysis

Référence

PLoS ONE. 2018 ;13(3):e0194329